Member access

4-Traders Homepage  >  Shares  >  NATIONAL STOCK EXCHANGE OF INDIA  >  Ranbaxy Laboratories Limited    RANBAXY   INE015A01028

End-of-day quote. End-of-day quote NATIONAL STOCK EXCHANGE OF INDIA - 01/28
698.75 INR   -1.31%
12:03p RANBAXY LABORAT : Q3FY 2015 Sales Rs.25,876Mn. YTD Dec’14 Sale..
06:00aDJRanbaxy Laboratories Returns to a Loss in Oct-Dec
05:04a RANBAXY LABORAT : -stock exchange statement
SummaryQuotesChart AnalysisNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Ranbaxy Resumes Generic Lipitor Production for U.S.

02/22/2013 | 12:05pm US/Eastern

Ranbaxy Laboratories Ltd. (500359.BY) said Friday it has resumed manufacturing generic copies of the cholesterol-lowering drug Lipitor for the U.S. market, following a production suspension late last year after tiny glass particles were found in the product.

Ranbaxy voluntarily recalled about 480,000 bottles of generic Lipitor, also known as atorvastatin calcium, in the U.S. in November, after discovering the glass fragment problem.

An Indian unit of Japan's Daiichi Sankyo Co. (DSNKY, 4568.TO), Ranbaxy said Friday it's working with the U.S. Food and Drug Administration as it implements corrective actions designed to prevent future manufacturing problems.

Ranbaxy has commenced production of the drug substance for its atorvastatin product, as part of the first step toward resuming supplies to the U.S. market, the company said in a statement.

The recall didn't affect Ranbaxy's generic Lipitor product outside the U.S.

In January, Ranbaxy said it completed an investigation of the manufacturing problem that caused the glass particles to turn up in the product. The company previously said it suspected that a faulty tank at a facility in India caused the problem.

Ranbaxy was one of the biggest sellers of generic Lipitor in the U.S. after Pfizer Inc. (>> Pfizer Inc.) lost exclusivity for the branded product in late 2011.

But Ranbaxy's share of the generic Lipitor market has plunged to 2% from about 45% before the recall, according to J.P. Morgan, which cited data from IMS Health. Other generic companies including Mylan Inc. (>> Mylan Inc.) and Apotex Inc. have gained share of the generic Lipitor market.

Write to Peter Loftus at

Subscribe to WSJ:

Stocks mentioned in the article : Mylan Inc., Pfizer Inc.
React to this article
12:17p DILIP SHANGHVI : Is Shanghvi readying a succession plan?
12:03p RANBAXY LABORATORIES : Q3FY 2015 Sales Rs.25,876Mn. YTD Dec’14 Sales Rs.81..
06:28a Sun pharma chief expects ranbaxy deal to close by mid-feb 2015
06:00aDJRanbaxy Laboratories Returns to a Loss in Oct-Dec
05:04a RANBAXY LABORATORIES : -stock exchange statement
01/27 DILIP SHANGHVI : Dilip shanghvi
01/27 RANBAXY LABORATORIES : Sun pharma open to fresh acquisitions
01/16 Generics beat trend in 2014, clock 14.4% growth in sales
01/14 RANBAXY LABORATORIES : Sun set to push ranbaxy's brands
01/13 Top five m&a deals involving indian companies
Duration : Period :
Ranbaxy Laboratories Limit Technical Analysis Chart | RANBAXY | INE015A01028 | 4-Traders
Income Statement Evolution
More Financials
Dynamic quotes